SCHEMBL26268656

SCHEMBL26268656

Cc1ncc(-c2nc(NC3CCN(SCCO)CC3)ncc2C(F)(F)F)s1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 17/20 0.43
▸ CCNE1 P24864 16/20 0.43
▸ CDK1 P06493 12/20 0.41
▸ CCNB1 P14635 12/20 0.41
▸ CDK4 P11802 11/20 0.41
▸ CCND1 P24385 11/20 0.41
▸ CCND3 P30281 10/20 0.41
▸ CDK6 Q00534 10/20 0.41
▸ CCNT1 O60563 6/20 0.41
▸ CDK9 P50750 6/20 0.41
▸ CDK7 P50613 4/20 0.41
▸ CCNH P51946 4/20 0.41
▸ MNAT1 P51948 4/20 0.41
▸ ULK1 O75385 1/20 0.38
▸ CCNK O75909 2/20 0.37
▸ CDK12 Q9NYV4 2/20 0.37
▸ CCNA2 P20248 1/20 0.35
▸ CCNA1 P78396 1/20 0.35
▸ MAPK3 P27361 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26268376 0.90 CDK2 (0.45) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL26267828 0.87 CDK2 (0.48) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL26268440 0.85 CDK2 (0.46) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL26268447 0.84 CDK2 (0.45) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL26268664 0.84 CCNE1 (0.38) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL27026817 0.83 CDK2 (0.47) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL25403192 0.82 CCNE1 (0.52) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL30537174 0.82 CCNE1 (0.52) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL27026844 0.81 CDK2 (0.48) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL30537182 0.80 CCNE1 (0.56) CDK2CCNE1CDK1CCNB1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-01-18 — — US disclosed
WO-2023172957-A1 THAIZOLE-PYRIMDIINE CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2023-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 CDK2 4/4885CCNE1 36/4885CDK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback